Home Posts tagged NSCLC

NSCLC

Pfizer
NEWS DESK

Five Year Follow-Up Data of Pfizer’s CROWN Trial Shows Prolonged Progression-Free Survival in ALK-Positive Advanced Lung Cancer

Pfizer has announced longer-term follow-up results from the Phase 3 CROWN trial, evaluating Lorlatinib, a lung cancer treatment in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After five years of median follow-up, median progression-free survival (PFS) based on investigator assessment showed an 81